IX Biopharma Widens Net Loss by 12% in FY2024
IX Biopharma Widens Net Loss by 12% in FY2024
ix生物制药在2024财年将净亏损扩大了12%
Loss per share stood at $0.0141 from $0.0126 a year ago.Loss per share stood at $0.0141.
每股亏损为0.0141美元。
iX Biopharma reported a net loss by 12% to $10.8m in FY2024 from $9.6m a year ago.
ix生物制药(FY2024)的净亏损为1080万美元，较去年同期的960万美元增长了12%。
Revenue for the period slipped 1% to $5.95m from $5.91m in FY2023, whilst gross profit fell 55% to $1.04m from $2.32m in FY2023.
该期间的营业收入从FY2023年的591万美元下降了1%至595万美元，而毛利润从FY2023年的232万美元下降了55%至104万美元。
Loss per share stood at $0.0141 from $0.0126 a year ago.
每股亏损为0.0141美元，而去年同期为0.0126美元。
资讯热榜
更新时间